A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu√©rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)